Physician profile
Nimish Patel
NPI 1598962458
$2,738.19
in general payments reported to CMS, 2019-2025
23 companies · $834 in 2025
The $834 reported for 2025 was more than what 76% of Otolaryngology providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $566 · 2020: $232 · 2021: $162 · 2022: $292 · 2023: $209 · 2024: $444 · 2025: $834.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,487.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,487.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $527.22 | 2020-2025 | |
| Stryker Corporation | $471.98 | 2019-2024 | Xpress Loprofile |
| Acclarent, INC | $405.79 | 2019-2024 | Acclarent Navwire, Acclarent Balloon Inflation Device, Relieva Ultirra |
| Intersect Ent, INC. | $210.80 | 2019-2021 | |
| Integra Lifesciences Corporation | $196.64 | 2025 | Relieva Spinplus Nav, Inspira Air, Acclarent Aera |
| Neurent Medical Limited | $170.12 | 2022-2025 | Neuromark Radiofrequency Console, Neuromark System, Neuromark Device |
| Regeneron Healthcare Solutions, INC. | $146.71 | 2019-2023 | Dupixent |
| Optinose US, INC. | $121.80 | 2021-2023 | |
| Inspire Medical Systems, INC. | $89.91 | 2024-2025 | Inspire |
| Olympus America INC. | $55.56 | 2019-2024 | Rhino-Laryngo Videoscope |
| Boston Scientific Corporation | $39.58 | 2025 | General - Kidney Stone Disease |
| Amgen INC. | $39.50 | 2025 | Tezspire |
| Medtronic, INC. | $37.25 | 2024 | Propel |
| Kowa Pharmaceuticals America, INC. | $36.01 | 2022-2025 | Zoryve |
| Hikma Pharmaceuticals USA | $35.51 | 2024-2025 | Ryaltris |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $33.07 | 2023-2025 | Nucala |
| Smith+Nephew, INC. | $25.23 | 2025 | Halo |
| Recor Medical INC | $24.50 | 2024 | Paradise Renal Denervation System |
| Cochlear Americas | $21.89 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $16.06 | 2025 | Tezspire |
| Alk-Abello, INC | $14.05 | 2019 | |
| Aerin Medical INC. | $11.53 | 2020 | |
| Spirair, INC. | $7.48 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nimish Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.